Are you at risk for prostate cancer after a negative Biopsy?
Research has shown that up to 30% of men with a negative/benign prostate biopsy result actually do have prostate cancer. The disease is very difficult to diagnose because a prostate biopsy samples less than 1% of your entire prostate gland. This means that prostate cancer might be present in one or more small tumors located in areas the biopsy needle did not sample.
If you and your urologist have concerns about your risk for undetected prostate cancer, Confirm MDX can provide more information after a negative biopsy by helping detect, at the molecular level, cancerous tumors that may be present anywhere in your prostate gland.
For Many Patients, Yes. The Test Results Provide Actionable Information to You and Your Urologist.
You are eligible to have Confirm MDX testing if you have received any of the following prostate biopsy results within a prior 30 month timeframe:
- Negative/benign
- HGPIN (high-grade prostatic intraepithelial neoplasia)
- Atypia (atypical glands suspicious for malignancy)
- ASAP (atypical small acinar proliferation)
- PIA (proliferative inflammatory atrophy, or lesion)
Confirm MDX is Performed on the Tissue from Your Prior Biopsy.
Confirm MDX for Prostate Cancer works at the DNA level to help identify undetected cancers. The test is able to detect abnormal DNA changes associated with the presence of prostate cancer. These changes cannot be seen by the standard microscopic evaluation traditionally used by pathologists to screen prostate biopsies.
Confirm MDX provides actionable information that can help your urologist determine if you are at risk for prostate cancer and determine your need for a repeat biopsy.
